NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
Neonc Technologies, Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Celgene
Daiichi Sankyo
Celgene
Pfizer
Eli Lilly and Company